Myopathy with Human Immunodeficiency Virus Type 1 (HIV-1) Infection: HIV-1 or Zidovudine?
- Michele Till, MD; and
- Keith B. MacDonell, MD
Excerpt
Recent data indicate that early therapy with zidovudine is beneficial in slowing disease progression in persons infected with the human immunodeficiency virus type 1 (HIV-1) when CD4 cell counts are less than 500 cells/ mm3 (1). Many persons infected with HIV-1 will be taking zidovudine over long periods, and clinicians may be faced with related complications. One such complication is the development of a drug-induced myopathy. Although muscle pathologies including inflammatory myopathy (2-5), type II atrophy (6), and nemaline rod myopathy (2, 7, 8) had been described in association with HIV-1 infection before use of zidovudine, there are now several
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
Requests for Reprints: Michele Till, MD, Section of Infectious Diseases, Northwestern University Medical School, Passavant Pavilion, Room 828, 303 East Superior Street, Chicago, IL 60611.
Most Read
